The Trump administration’s “Most Favoured Nation” (MFN) drug pricing campaign crossed a significant threshold on August 31, 2026, when nine additional pharmaceutical manufacturers — including India’s Sun Pharma — signed on, bringing the total to 26 companies that the White House says now represent close to 90 percent of the branded US pharmaceutical market. For an Indian pharma major, inclusion in an American federal pricing initiative of this scale is a genuinely unusual position to occupy, and it carries implications well beyond the immediate commercial terms.
The MFN framework, revived through a May 2025 executive order after featuring in Trump’s first term, requires participating companies to align their US drug prices with the lowest price they charge in comparable wealthy nations — a direct assault on the long-standing practice of US consumers subsidising lower drug prices charged elsewhere in the world. Under the deals, participating companies provide Medicaid discounts and commit to offering products through TrumpRx.gov, a direct-to-consumer pricing platform the administration launched in February 2026 as the public-facing showcase of the initiative. The nine companies added on August 31 — Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB — are collectively described by the administration as mid-sized manufacturers, distinct from the larger first-wave signatories like Pfizer, Eli Lilly and Novo Nordisk that joined earlier in the campaign. Collectively, the administration says the 26 deals are projected to save Americans upward of $600 billion, and pharmaceutical prices have in fact fallen for several consecutive months, dropping roughly 0.8 percent in July alone and down over 3 percent from a year earlier — the steepest annual decline the sector has recorded in more than six decades, according to the most recent US Consumer Price Index data.
Politically, the timing is not incidental. The administration has been explicit that highlighting falling drug prices is part of a broader healthcare affordability push ahead of November’s midterm elections, alongside calls for Congress to pass a wider “Great Healthcare Plan” addressing insurance premiums and price transparency. Whether the MFN framework’s savings claims hold up under independent scrutiny remains contested — critics have questioned whether headline figures like the $600 billion savings projection reflect enforceable structural change or front-loaded political messaging — but the underlying CPI data showing sustained monthly drug-price declines is independently verifiable and represents a genuine shift from the steady annual increases that characterised US pharmaceutical pricing for most of the past two decades.
For Sun Pharma, the world’s fourth-largest specialty generics company by revenue and a firm with deep US market exposure, MFN participation is best read as a defensive commercial calculation rather than a voluntary act of pricing generosity. Companies joining these deals have generally done so under the implicit threat of tariffs the administration has repeatedly floated against pharmaceutical importers who decline to cooperate, alongside commitments — collectively exceeding $150 billion across signatories — to expand US-based manufacturing and research investment. Whether Sun Pharma’s specific commitments under the deal will translate into announced US manufacturing expansion, as several Western pharma majors have already done, is a detail Indian trade and industry watchers will want to track closely in the coming months, since it speaks directly to whether MFN pressure accelerates a broader trend of API and formulation manufacturing shifting away from cost-advantaged locations like India toward reshored US facilities.
Running in parallel to the pricing story, and worth pairing in this issue because of its direct relevance to millions of Indian cardiology patients, is strengthening clinical evidence for SGLT2 inhibitors — a class of drugs originally developed for diabetes that has increasingly proven itself as foundational heart-failure therapy. A substantial body of meta-analytic evidence, spanning multiple independent systematic reviews of randomised controlled trials, has now consistently shown that SGLT2 inhibitors meaningfully reduce all-cause mortality and cardiovascular death in heart-failure patients, alongside reductions in heart-failure hospitalisation, with several pooled analyses reporting mortality hazard ratios in the range of 0.83 to 0.86 — meaning roughly a 15 to 17 percent relative reduction in death risk compared with placebo across the trials reviewed. It is worth an honest editorial caveat here: at least one recent large meta-analysis pooling 59 randomised trials found that while the mortality-reduction signal held, the certainty of that finding was rated low once researchers adjusted for potential publication bias — a reminder that even well-established drug classes benefit from continued scrutiny rather than treating early consensus as the final word. That caveat has not, however, stopped major guideline bodies from acting on the weight of evidence assembled so far.
That evidence base has grown robust enough that SGLT2 inhibitors are now recommended as foundational heart-failure therapy in major cardiology guidelines, including a joint statement issued by Europe’s and India’s Heart Failure Associations, a rare instance of Indian cardiology bodies co-authoring guidance alongside their European counterparts at this level of clinical consensus. For Indian cardiologists and health system planners, this matters practically: heart failure remains dramatically under-diagnosed and under-treated across much of India’s public health infrastructure, and a drug class with this strength of mortality evidence, priced within reach through generic manufacturing, represents a genuine public-health opportunity rather than merely an incremental clinical refinement.
The two stories intersect in a way NSH readers with pharma-industry interests should note directly: several SGLT2 inhibitor manufacturers, including major multinational signatories to the MFN programme, are among the companies whose US pricing is now directly regulated by these deals, meaning the drug-pricing and cardiology-evidence threads are not merely thematically adjacent but commercially entangled. As Indian patients increasingly gain access to SGLT2 inhibitors through both branded and generic channels — with Indian manufacturers, including Sun Pharma itself, playing a significant role in global generic SGLT2 inhibitor supply — the interplay between US pricing policy, global manufacturing economics and clinical guideline adoption in India represents exactly the kind of cross-cutting pharma story that deserves sustained editorial attention through 2026 and into next year, as both the MFN programme’s midterm-election-driven momentum and the cardiology evidence base continue to evolve.
– Uday Sasikiran Thota
